DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is set to present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.
The recorded presentation will be available on the Investors section of the Company’s website at https://ir.diamedica.com/events-and-presentations beginning Monday, January 11th.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005244/en/